Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion

[1] Ahlskog JE(2001)Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 448-458

[2] Muenter MD(2019)Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study J Neurol 266 2164-2176

[3] Lopiano L(2021)the long-term impact of levodopa/carbidopa intestinal gel on ‘off’-time in patients with advanced Parkinson’s disease: a systematic review Adv Ther 38 2854-2890

[4] Modugno N(2012)Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease Eur J Neurol 19 1079-1085

[5] Marano P(2022)Psychometric properties of clinical indicators for identification and management of advanced Parkinson’s disease: real-world evidence from G7 countries Neurol Ther 34 2063-2073

[6] Sensi M(2018)Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach Curr Med Res Opin 84 1669-1672

[7] Meco G(2015)Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease Neurology 38 90-92

[8] Solla P(2017)Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up Parkinsonism Relat Disord 76 98-103

[9] Gusmaroli G(2020)Beyond 10 years of levodopa intestinal infusion experience: analysis of mortality and its predictors Parkinsonism Relat Disord 10 935-944

[10] Tamma F(2020)Predictors of time to discontinuation of levodopa-carbidopa intestinal gel infusion: a retrospective cohort study J Parkinsons Dis 25 2649-2653

[1] Ahlskog JE(2001)Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 448-458

[2] Muenter MD(2019)Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study J Neurol 266 2164-2176

[3] Lopiano L(2021)the long-term impact of levodopa/carbidopa intestinal gel on ‘off’-time in patients with advanced Parkinson’s disease: a systematic review Adv Ther 38 2854-2890

[4] Modugno N(2012)Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease Eur J Neurol 19 1079-1085

[5] Marano P(2022)Psychometric properties of clinical indicators for identification and management of advanced Parkinson’s disease: real-world evidence from G7 countries Neurol Ther 34 2063-2073

[6] Sensi M(2018)Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach Curr Med Res Opin 84 1669-1672

[7] Meco G(2015)Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease Neurology 38 90-92

[8] Solla P(2017)Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up Parkinsonism Relat Disord 76 98-103

[9] Gusmaroli G(2020)Beyond 10 years of levodopa intestinal infusion experience: analysis of mortality and its predictors Parkinsonism Relat Disord 10 935-944

[10] Tamma F(2020)Predictors of time to discontinuation of levodopa-carbidopa intestinal gel infusion: a retrospective cohort study J Parkinsons Dis 25 2649-2653